Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: breast cancer + zometa + cancer  Related to the article below (Last Update: 8/5/2008)

Drug shows promise treating breast cancer
St. Louis Post-Dispatch,  United States -
The finding was similar to that of a large trial in Europe that showed Zometa may help prevent the spread of breast cancer. "Those studies are both out and ...

TopNews
Bone Density Predicts Chances of Breast Cancer
Washington Post, United States - Jul 28, 2008
By Amanda Gardner MONDAY, July 28 (HealthDay News) -- Calculating a woman's bone mineral density appears to shed light on her risk for breast cancer. ...
Study Finds Causal Relationship Between High Bone Density and ... eFluxMedia
all 54 news articles »
Roseburg women share cancer
NRToday.com, OR - Jul 23, 2008
One drug, Zometa, blocks the holes formed in Morgan?s bones from the chemotherapy. The other drug, Herceptin, blocks the cancer cells from growing and ...
Novartis gains momentum with strong performance in first half of ...
Ad-Hoc-News (Pressemitteilung), Germany - Jul 16, 2008
Zometa demonstrated for the first time a significant benefit for premenopausal women with hormone-sensitive, early-stage breast cancer. ...NVS - BOM:500672 - ACL
Novartis Second-Quarter Net Rises 17% on Diovan Sales (Update1)
Bloomberg - Jul 16, 2008
Earlier this week, Genentech Inc., the biggest US maker of cancer drugs, raised its 2008 forecast and said second-quarter profit increased 4.7 percent on ...NVS

OverTheLimit.info
Study Links High Bone Mineral Density (BMD) With Breast Cancer
TopNews, India - Jul 29, 2008
The US Researchers, in a new study, found a connection between high bone mineral density (BMD) and increased chances of developing breast cancer in ...
Study: High Bone Mineral Density May Indicate The Risk Of ... TopNews
all 20 news articles »
Novartis Gains Momentum With Strong Performance In First Half Of ...
ABN Newswire (press release), Australia - Jul 16, 2008
Femara (USD 561 million, +19% lc), an oral therapy for women with hormone-sensitive breast cancer, outpaced competitors and gained share in the aromatase ...NVS
Novartis (NVS): Big Pharma's best pipeline
BloggingStocks - Jul 7, 2008
We also got word that its bone drug Zometa reduced the risk of breast cancer recurring by 35% in an 1800 person trial. "The favorable news earned Novartis ...NVS
Influence of Musculoskeletal Conditions on Oral Health Among Older ...
RedOrbit, TX - Jul 10, 2008
37 Again, most of the cases were cancer patients who had received intravenous bisphosphonates, but a few had taken oral alendronate or risedronate for ...
Pr?vention et traitement des l?sions osseuses du my?lome
H?matologie, France - Jul 24, 2008
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer ...
Source: Google News

… 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer -
BE Hillner, JN Ingle, RT Chlebowski, J Gralow, GC … - Journal of Clinical Oncology, 2003 - jcojournal.org
... ASCO SPECIAL ARTICLE. American Society of Clinical Oncology 2003 Update on the Role
of Bisphosphonates and Bone Health Issues in Women With Breast Cancer. ...

Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors -
A Bamias, E Kastritis, C Bamia, LA Moulopoulos, I … - Journal of Clinical Oncology, 2005 - jco.ascopubs.org
... palliative treatment in women with breast carcinoma and ... Cancer 88: 1082-1090,
2000[CrossRef][Medline]; Package ... Osteonecrosis of the jaw: Zometa (zoledronic acid ...

Optimising treatment of bone metastases by Aredia (TM) and Zometa (TM). -
RE Coleman - Breast Cancer, 2000 - ncbi.nlm.nih.gov
... myeloma or breast cancer with bone metastases. Current research aims include the
evaluation of new potent bisphosphonates such as zoledronic acid (Zometa(TM)). ...

The New Bisphosphonate, Zometa?(Zoledronic Acid), Decreases Skeletal Complications in Both … -
A Lipton, E Small, F Saad, D Gleason, D Gordon, M … - Cancer Investigation, 2002 - informaworld.com
... The New Bisphosphonate, Zometa ... Hershey, PA 17003 2 UCSF Mount Zion Cancer Center,
San ... treatment of choice for lytic bone lesions associated with breast cancer. ...

… Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid … -
LS Rosen, D Gordon, S Tchekmedyian, R Yanagihara, … - Journal of Clinical Oncology, 2003 - jcojournal.org
... skeletal metastases in patients with breast cancer or osteolytic ... Cancer J 7:377?387,
2001[Medline]; Lipton A ... al: The new bisphosphonate, ZOMETA (zoledronic acid ...

… Acid Inhibits Adjuvant Letrozole-Induced Bone Loss in Postmenopausal Women With Early Breast Cancer -
A Brufsky, WG Harker, JT Beck, R Carroll, E Tan- … - Journal of Clinical Oncology, 2007 - jco.ascopubs.org
... up, results of the primary end point of the Zometa-Femara Adjuvant ... the LS in
postmenopausal women receiving adjuvant letrozole for early-stage breast cancer. ...

Safety and Efficacy of Bisphosphonates Beyond 24 Months in Cancer Patients -
SM Ali, FJ Esteva, G Hortobagyi, H Harvey, J … - Journal of Clinical Oncology, 2001 - jco.ascopubs.org
... Treatment of osteolytic disease in breast cancer and multiple myeloma patients with ...
This agent, Zometa (zoledronic acid for injection; Novartis Pharmaceutical ...

… of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer … -
A Brufsky - Semin Oncol, 2006 - ncbi.nlm.nih.gov
... with letrozole is currently being investigated in the Zometa/Femara Adjuvant ... positive
and/or progesterone-receptor-positive breast cancer starting letrozole ...

Zoledronic Acid-Related Angiogenesis Modifications and Survival in Advanced Breast Cancer Patients -
B Vincenzi, D Santini, G Dicuonzo, F Battistoni, M … - Journal of Interferon & Cytokine Research, 2005 - liebertonline.com
... for the study if they had a histologically confirmed breast cancer associated with ...
All patients received 4 mg zoledronic acid (Zometa, Novar- tis, Basilea) in ...

… of Pamidronate Disodium for the Palliation of Bone Pain in Men With Metastatic Prostate Cancer -
EJ Small, MR Smith, JJ Seaman, S Petrone, MO … - Journal of Clinical Oncology, 2003 - jco.ascopubs.org
... F, et al: The new bisphosphonate ZOMETA TM (zoledronic ... Cancer Invest 20:45?47, 2001
(suppl 20; abstr ... 2 dose-ranging trials in patients with breast or prostate ...

Source: Google Scholar
 
 

Zometa improves BMD in breast cancer patients receiving adjuvant therapy

 
 
Zoledronic Acid ( Zometa ), an intravenous bisphosphonate, was shown to inhibit aromatase inhibitor-induced bone loss in postmenopausal women treated with Letrozole ( Femara ) in the adjuvant breast cancer setting.

Final data of the primary endpoint of 12-month bone mineral density ( BMD ) demonstrate a significant increase in BMD for those breast cancer patients treated with Femara and upfront Zometa compared with those who received Femara and delayed Zometa.

Several studies have shown that women treated with hormonal therapy in the adjuvant breast cancer setting are at risk of bone loss.
New data from the Z- FAST ( Zometa-Femara Adjuvant Synergy Trial ) study offer evidence that Zometa may prevent bone loss in these patients.
These data are particularly important given that aromatase inhibitors are a widely prescribed hormonal therapy for newly diagnosed breast cancer.

The Z-FAST study showed that at the 12-month follow-up, the group of patients receiving upfront Zometa had a mean increase of lumbar spine BMD of 1.9% vs. a decrease of 2.4% in the group of patients who received delayed Zometa ( p<0.0001 ).
This represents a 4% relative difference in lumbar spine BMD in favor of the upfront Zometa group.
Total hip BMD was also significantly higher in the upfront group, compared to the delayed group.
Significantly, 8% of patients in the delayed group had decreases in BMD at the 12-month follow-up, which required initiation of Zometa.

Zometa is generally well tolerated in non-metastatic cancer patients.
The following adverse events occurred in more than 5% of patients in the Z-FAST study: arthralgia ( 30% in upfront group, 29% in delayed group ); hot flashes ( 25.3%, 25.7% ); fatigue ( 17.3%, 15.3% ); myalgia ( 12.7%, 9.7% ); bone pain ( 11.3%, 4% ); headache ( 9%, 7.3% ); nausea ( 8%, 5.7% ); pain in extremities ( 8%, 4.3% ); insomnia ( 7%, 5.3% ); depression ( 5.7%, 9% ) back pain ( 6%, 5.7% ).

The Z-FAST study is part of a wider clinical program that includes the international sister trial Zo-FAST.
Zo-FAST, which will include more than 900 patients in 30 countries outside the U.S., is investigating the same primary and secondary endpoints and will add to this body of clinical evidence.

Zometa was granted marketing authorization by the FDA in February 2002 for the treatment of bone complications in patients with advanced malignancies involving bone.
Zometa is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy.
In prostate cancer, patients should have progressed after treatment with at least one hormonal therapy.
The solid tumors studied included, among others, prostate, breast, lung, renal and colon. Zometa also is indicated for the treatment of hypercalcemia of malignancy ( HCM ), the most common life-threatening metabolic complication of cancer.

Zometa has been associated with reports of renal insufficiency. Patients should have serum creatinine assessed prior to receiving each dose of Zometa.
Caution is advised when Zometa is used in Aspirin sensitive patients, or with aminoglycosides, loop diuretics, and other potentially nephrotoxic drugs.
Due to the risk of clinically significant deterioration in renal function, single doses of Zometa should not exceed 4 mg and the duration of infusion should be no less than 15 minutes in 100 ml of diluent.

In clinical trials in patients with bone metastases and hypercalcemia of malignancy ( HCM ), Zometa had a safety profile similar to other intravenous bisphosphonates.
The most commonly reported adverse events included flu-like syndrome ( fever, arthralgias, myalgias, skeletal pain ), fatigue, gastrointestinal reactions, anemia, weakness, cough, dyspnea and edema.

Zometa should not be used during pregnancy.

Zometa is contraindicated in patients with clinically significant hypersensitivity to Zoledronic Acid or other bisphosphonates, or any of the excipients in the formulation of Zometa.

Osteonecrosis of the Jaw ( ONJ ) has been reported in patients with cancer receiving treatment including bisphosphonates, chemotherapy, and/or corticosteroids.
The majority of reported cases have been associated with dental procedures such as tooth extraction.
A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with concomitant risk factors.
While on treatment, these patients should avoid invasive dental procedures if possible.
No data are available as to whether discontinuation of bisphosphonate therapy reduces the risk of ONJ in patients requiring dental procedures.

Source: 41st Annual Meeting of the American Society of Clinical Oncology ( ASCO ), 2005
 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News2 ; News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 © 2002-2006

Keywords::

Contact Iconocast

Home Page